Statera BioPharma (FRA:7CB) Retained Earnings: €-145.52 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Retained Earnings?

Statera BioPharma FRA:7CB 20 Retained Earnings is €-145.52 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Statera BioPharma's retained earnings for the quarter that ended in Sep. 2022 was €-145.52 Mil.

Statera BioPharma's quarterly retained earnings declined from Mar. 2022 (€-124.61 Mil) to Jun. 2022 (€-133.13 Mil) and declined from Jun. 2022 (€-133.13 Mil) to Sep. 2022 (€-145.52 Mil).

Statera BioPharma's annual retained earnings declined from Dec. 2019 (€-13.98 Mil) to Dec. 2020 (€-22.82 Mil) and declined from Dec. 2020 (€-22.82 Mil) to Dec. 2021 (€-114.59 Mil).


Statera BioPharma  (FRA:7CB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Statera BioPharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Retained Earnings Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Retained Earnings
-13.98 -22.82 -114.59

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -44.42 -114.59 -124.61 -133.13 -145.52
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-145.52 Mil mean?
Statera BioPharma (FRA:7CB) has a Retained Earnings of €-145.52 Mil as of Sep. 2022. Retained earnings is the amount of net income not issued to shareholders. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Retained Earnings too high?
Statera BioPharma's current Retained Earnings is €-145.52 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Retained Earnings compare to NRBO and PALI?
Statera BioPharma's Retained Earnings of €-145.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Retained Earnings is €-145.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Retained Earnings of €-145.52 Mil. The current Retained Earnings is €-145.52 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Retained Earnings is €-145.52 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price